Current Research Journal of Biological Sciences 5(4): 182-189, 2013 ISSN: 2041-076X, e-ISSN: 2041-0778 © Maxwell Scientific Organization, 2013 Submitted: March 02, 2013 Accepted: March 27, 2013

Published: July 20, 2013

# Cloning and Characterization of Multiple RNA Splicing Variants of *LDH-C* Gene in Human and Rat

<sup>1</sup>Qinglian Zhang, <sup>1</sup>Min Yang, <sup>1</sup>Jiagui Jin, <sup>2</sup>Qinghua He and <sup>2</sup>Jinhu Ma <sup>1</sup>School of Laboratory Medicine, Chengdu Medical College, Chengdu, Sichuan, 610500, <sup>2</sup>College of Life Science and Technology, Southwest University for Nationalities, Chengdu, Sichuan, 610041, Peoples' Republic of China

**Abstract:** The expression of LDH-C (Lactate dehydrogenase C) gene is restricted in mature germ cells; however multiple splice variants of LDH-C expressed in human cancers and yak normal testes were reported recently. In order to know if there are any LDH-C splice variants in human normal testes, we set out to clone the putative variants in human and rat. Four splicing variants in human testes, 1 splicing variant in human spermatozoa, 6 splicing variants in rat testes and 1 splicing variant in rat non-testes tissues (liver, heart and muscle) were cloned. The putative polypeptides encoded by these variants were compared with the full-length LDH-C protein, the results showed that these putative polypeptides were truncated LDH-C proteins or truncated LDH-C proteins with a few amino acid residues different at N or C terminal. This suggested that these variants are possibly not used for translation, but targets of nonsense-mediated mRNA decay. Western blotting did not detect any bands with similar molecular weight as the putative polypeptides. RT-PCR showed that the expression levels of the splicing variants were significant during development of rat testes. The results indicate that LDH-C was not silenced by transcriptional repression in non-mature germ cells, but significantly transcripted and alternatively spliced.

Keywords: Alternative splicing, development, expression regulation, lactate dehydrogenase c, splicing variant

# **INTRODUCTION**

Mammalian Lactate dehydrogenase (LDH: EC1.1.1.27) protein family is a kind of tetrameric NAD<sup>+</sup>-specific dehydrogenases and serves as the terminal enzyme of glycolysis, catalyzing reversible oxidation-reduction reaction between pyruvate and lactate (Everse and Kaplan, 1973). There are three different subunits of LDH in mammalian, comprising LDH-A, LDH-B and LDH-C, encoded by three different genes, LDH-A, LDH-B and LDH-C, respectively. Although the LDH isozymes catalyze the interconversion between pyruvate and lactate, each has presumed function and specific distribution pattern (Everse and Kaplan, 1973). LDH-A is most active in skeletal muscle and other tissues where oxygen deficiency happens frequently and glycolysis is required to satisfy metabolic needs, while LDH-B is abundantly expressed in cardiac muscle and liver that is dependent upon aerobic metabolism pathways. An exquisite tissue distribution is displayed by LDH-C, the third member of the family, which is found only in male (Goldberg, 1985) and female (Coonrod et al., 2006) germ cells.

Many researchers are interested in LDH-C due to its tissue specific distribution. The restriction of LDH-C

to germ cells but not in any somatic tissues makes it an ideal model gene for studying the regulation of tissuespecific expression (Tang et al., 2008). In somatic cells, the suppression of LDH-C gene expression is likely due to methylation of CpG island of LDH-C promoter, however it still remains to be illustrated solidly (Tang and Goldberg, 2009). In germ cells, transcriptional analysis of LDH-C is compromised by the lack of a reliable cell culture system. Even so Goldberg and his colleagues made progress in elucidating the regulation of LDH-C gene expression by construction of transgenic mice and transfection of germ cells in situ (Li et al., 1998; Markert et al., 1998). They identified some potential *cis*-regulatory elements including PAL, GC box and CRE and trans-acting factors including Sp and CREB, they suggested that the role of the CRE site is essential for spermatocyte-specific gene expression (Tang et al., 2008; Tang and Goldberg, 2009; Kroft et al., 2003). However, the mechanisms governing LDH-C expression and tissue specificity are largely unknown.

Koslowski *et al.* (2002) reported that the expression of multiple splicing variants of LDH-C occurred selectively in human cancer. They discovered that LDH-C escapes from transcriptional repression, resulting in significant expression level of splicing

Corresponding Author: Qinghua He, College of Life Science and Technology, Southwest University for Nationalities, Chengdu, Sichuan, 610041, Peoples' Republic of China

variants in virtually all tumor types they tested (Koslowski *et al.*, 2002). They discovered the aberrant splicing patterns of *LDH-C* restricted to tumor cells and expression of LDH-C in tumors is neither mediated by gene promotor demethylation, as previously described for other germ cell-specific genes activated in cancer, nor induced by hypoxia as demonstrated for enzymes of the glycolytic pathway. The author, thus, estimated the specific expression pattern may have something to do with the unique energy metabolism of cancer cells and LDH-C activation in cancer may provide a metabolic rescue pathway in tumor cells by exploiting lactate for ATP delivery.

Recently, He and colleagues reported that LDH-C multiple splicing variants were detected in some mammals' testes (He *et al.*, 2008; Huang *et al.*, 2012). It seems that the splicing variants does not restricted to tumors.

Are there any splicing variants in human normal testes just like in yaks? To answer this question, we started to clone LDH-C cDNA from human normal testes and spermatozoa. Surprisingly, we found 5 alternative splicing variants in non-cancer human testes and spermatozoa. Six splicing variants were also cloned in rat testes and non-testes tissues and expression profiles of different LDH-C splicing variants were investigated in rat. The results indicate that LDH-C was not silenced by transcriptional repression in non-mature germ cells, but significantly transcripted and alternatively spliced.

# MATERIALS AND METHODS

**Materials:** Human testis was obtained from The First Hospital affiliated to Chengdu Medical College (Chengdu, China) after obtaining a signed informing consent and the approval of the Ethical Committee of this college. The tissue was immediately cryostored in liquid nitrogen after surgery. Human semen samples were obtained from 8 consenting donors who met all the World Health Organization (WHO) criteria for normozoospermia by masturbation after 3-5 d of abstinence (WHO, 1999). SD rats were from the experimental animal breeding center of Sichuan University

**RNA extraction and first stranded cDNA synthesis:** Total RNA from liquid nitrogen frozen human testis, ejaculated spermatozoa and rat tissues were extracted with Trizol Reagent (Invitrogen, Carlsbad, CA, USA) according to the manufacturer's instruction. The purity

Table 1. Drimer

of RNA samples was checked by spectrophotometer at 260 n and 280 nm and agarose electrophoresis. The first strand cDNA was synthesized using a TaKaRa RNA PCR Kit (AMV) Ver. 3.0 and 1  $\mu$ g of total RNA in the presence of 9 mers random primer (TaKaRa, Kyoto, Japan). All the procedures were in accordance with the instruction manual.

Cloning of LDH-C splicing variants from human and rat: The specific primers (Table 1) for cloning were designed based on the human LDH-C nucleotide sequence (GenBank accession number: BC064388.1) and rat LDH-C nucleotide sequence (GenBank accession number: NM 017266). The primers were used to amplify the entire Open Reading Frame (ORF) of human and rat LDH-C cDNA. To exclude falsepositive PCR products because of contaminating genomic DNA in the RNA preparation, all primer sets were evaluated by PCR reactions using either genomic DNA or non-reverse-transcribed RNA as negative controls. The PCR were performed in two rounds (Protocols listed in Table 2) and 0.5 µL PCR products of the first round were taken as the template for the second round. The PCR products were purified by purification kit (TaKaRa) to exclude DNA fragments less than 100 bp and then cloned into pMD18-T vector (TaKaRa) and direct colony PCR method was used to screen plasmids containing splicing variants with different fragment length. All selected clones were sequenced from both strand directions using BcaBEST<sup>TM</sup> Sequencing Primer RV-M and Sequencing Primer M13-47 (TaKaRa). The sequence data from this study have been deposited in GenBank under accession HQ386000-HQ386005 number (human) and JQ409364-JQ409369 (rats)

**Sequence analysis:** All the sequences were analyzed using the vector NTI Suite 9 software package (Invitrogen). The splicing variant cDNA sequences were aligned to the mRNA sequence of LDH-C (accession number: human, BC064388.1; rat, NM\_017266) containing the full length ORF. The missing or extra sequence were then align to the genomic sequence of LDH-C (accession number: human, NC\_000011; rat, NC\_005100) to see which exon was skipped or which intron was spliced in.

**RT-PCR analysis of LDH-C expression in rat testes:** The RT-PCR was performed using primer rps and rpa and the synthesized cDNA as template. In the first round, 5  $\mu$ L cDNA was taken as the template; in the

	Sense primer	Antisense primer
Human	hps1: 5'-TCTGGTGTCACTTCTGTGCCTTC-3'	hpa: 5' -TTCTGTTCTCCAAACAGTGGAACA-3'
	hps2: 5' -ATGTCAACTGTCAAGGAGCAGCTAA-3'	-
Rats	rps: 5'- ATGTCCACTGTCAAGGAGCAGCTAAT-3'	rpa: 5'-TAATTGCAGATCTTTCTGGATG-3'
	ppiaps: 5'-ATACGGGTCCTGGCATCT-3'	ppiapa: 5'-CCATCCAACCACTCAGTCTT-3'

Table 2.	PCR	protocols
1 auto 2.	IUN	protocois

	PCR protocols
Human LDH-C variants cloning from testis and spermatozoa	Round 1: 20 cycles×(94°C, 30 s; 55.3 °C, 30 s; 72°C, 1 min)
	Round 2: 20 cycles×(94°C, 30 s; 55.3 °C, 30 s; 72°C, 1 min), 72°C, 10 min
Rat LDH-C variants cloning from testis	Round 1: 20 cycles×(94°C, 30 s; 49 °C, 30 s; 72°C, 1 min)
	Round 2: 20 cycles×(94°C, 30 s; 49 °C, 30 s; 72°C, 1 min), 72°C, 10 min
Rat LDH-C variants cloning from heart, muscle and liver	Round 1: 30 cycles×(94°C, 30 s; 49 °C, 30 s; 72°C, 1 min)
	Round 2: 30 cycles×(94°C, 30 s; 49 °C, 30 s; 72°C, 1 min), 72°C, 10 min
RT-PCR analysis of LDH-C expression in rat testis	Round 1: 20 cycles×(94°C, 30 s; 49 °C, 30 s; 72°C, 1 min)
	Round 2: 20 cycles×(94°C, 30 s; 49 °C, 30 s; 72°C, 1 min)
RT-PCR analysis of PPIA expression in rat testis	Round 1: 20 cycles×(94°C, 30 s; 49 °C, 10 s; 72°C, 10 s)
	Round 2: 20 cycles×(94°C, 30 s; 49 °C, 10 s; 72°C, 10 s)

second round, 0.5  $\mu$ L PCR products of the first round was taken as the template. The PCR protocols were listed in Table 2. After two rounds of PCR, the products were analyzed by agarose electrophoresis. In parallel, the housekeeping gene PPIA (peptidylprolyl isomerase A) was amplified and set as loading control. The primers for PPIA were ppiaps and ppiapa (Table 1), the PCR protocol was listed in Table 2, in the first round, 1 $\mu$ L cDNA was taken as the template and in the second round, 0.5  $\mu$ L PCR products of the first round was taken as the template. After two rounds of PCR, the products were analyzed by agarose electrophoresis.

**SDS-PAGE and western blotting analysis:** Fresh tissues from SD rat were homogenated in extraction buffer (100mM sodium phosphate pH 7.0, plus 1mM EDTA and 1mM DTT). After centrifugation for 20 min at 15,000 g, the supernatant was used for SDS-PAGE. Five microliter supernatant was loaded with the same volume of loading buffer (contained 0.1% bromophenol blue, 20% glycerol and 4% ß-mercaptoethanol). Proteins were separated by 12% SDS-PAGE gel.


After SDS-PAGE proteins were transferred onto PVDF membrane (Millipore) immediately. The membranes were incubated in blocking buffer [TBS with 0.05% Tween-20 (TBS-T) plus 2% BSA] for 1 h at room temperature with gentle shaking. Then the membranes were washed in TBS-T for 5 min and incubated with the primary antibody H-160 (Santa Cruz, California, USA, H-160 were raised against amino acids 173-332 mapping at the C-terminus of LDH-A of human origin and can be used to detect LDH-A, B, C of rat). After several stringency washes, the membranes were incubated for 1 h at RT with the appropriate HRP-conjugated secondary antibody (BA1060, Boster, Wuhan, China). Finally the Amersham ECL kit (GE Healthcare Bio-Sciences Corp.) was used to detect the signal.

# RESULTS

**Cloning of LDH-C splicing variants in human and rats:** We had checked to make sure that primers were specific for LDH-C without cross-amplification of the related ubiquitously expressed isoenzymes LDH-A and LDH-B. The primers were designed to amplify the entire ORF of LDH-C gene and the expected size of PCR amplification product was about 1 kb (full length ORF) according to human and rat LDH-C gene. Clones that show less or more than 1 kb bands were selected and sent to sequencing. Several hundreds of clones were screened and suspected clones were sequenced. Finally 4 splicing variants in human testes, 1 splicing variant in human spermatozoa, 6 splicing variants in rat testes and 1 splicing variant in rat non-testes tissues (liver, heart and muscle) were cloned (Fig. 1).

Sequence analysis of human LDH-C splicing variants: The 5 cloned human splicing variants were missing exons or certain numbers of nucleotides in different manners (Fig. 1a). In detail, variant 1 and the full length cDNA differ in their 5' untranslated region because of alternative partial insertion of intron 1 (54 bp at 5' end), but they give rise to the same protein of 332 amino acids. Variant 2 was inserted by part of intron 1 (54 bp at 5' end) and missing entire exon3 and consequently gave two ORFs, V2-1 and V2-2. V2-1 was deficient in NAD binding domain and lost the entire active site, V2-2 was deficient in the NAD binding domain, but did contain the entire active site. Variant 3 missed the entire exon 3, 4, 5, 6, 7 and lost the entire NAD binding domain and the active site. Variant 4 lacked the first 78 bp of exon 5 but contained both the entire NAD binding domain and the active site. Variant 5 (the variant found in spermatozoa) missed the partial exon 2 (71 bp at 3' end) and 7 (102 bp at 5' end) and the entire exon 3, 4, 5, 6 and lost the entire NAD binding domain and the active site. All variants except for variant 5 use the same start codon as the full length LDH-C mRNA for protein translation. The putative polypeptides (more than 50 amino-acid residues polypeptides were considered) encoded by human LDH-C splicing variants were compared with the full length LDH-C protein, the results showed that most of these putative polypeptides were truncated LDH-C proteins except the polypetides encoded by ORF1 of variant 2 (V2-1) which was a truncated protein but with 9 amino acid residues at C-terminal different from LDH-C (Fig. 2a).

**Sequence analysis of rat LDH-C splicing variants:** The 6 cloned rat splicing variants were missing exons or certain numbers of nucleotides in different manners (Fig. 1b). In detail, variant 1 lacked the entire exon 5



Curr. Res. J. Biol. Sci., 5(4): 182-189, 2013

(b) Exon schematics of variants in rat

Fig. 1: Exon Schematics of LDH-C splicing variants detected in human (A) and in rat (B). The ORFs supposed to translate are marked; black bars represent lactate dehydrogenase NAD binding domain and Os represent lactate dehydrogenase active site

# Curr. Res. J. Biol. Sci., 5(4): 182-189, 2013

( )	1	10		20	30	40	50	60	70	80	90	100	114
												/TAGARQQEGET	
												/TAGARQQEGET	
10 V4 (1)	MST	VKEQLIEK	LIEDDENS	QCKITIVG	I'GAVGMAC	AISILL	(DLADELALVI	DVALDKLKGEM	MDLQHGSLFF	STSKITSGKDY	SVSANSRIVIV	/TAGARQQEGET	RLALVQRN
VZ-1 (1) n.V2 (1)	MST	VKEQLIEK	LIEDDENS	QCKITIVG.	I'GAVGMAC	AISILL	TIANTÓIDE						
n.\/5 (1) n.\/5 (1)	MS1	VKEQUIEK	TIFDDFN2	QCKIIIVG.		.AT2100.							
10 v3 (1) vV2-2 (1)													
·· (1)													
		120	130	140		150	160	170	180	190	200	210	2
ULL(115)	AIMK	SIIPAIV	HYSPDCKI	LVVSNPVD:	ILTYIVWK	ISGLPV	TRVIGSGCNL	DSARFRYLIG	EKLGVHPTSCH	HGWIIGEHGDS	SVPLWSGVNVA	AGVALKTLDPKI	GTDSDKEH
												AGVALKTLDPKI	
												AGVALKTLDPKI	
101 (50)													
<u>, (12)</u>													
vV5 (1)													
/2-2 (1)	MK	VIZGTTDATV	אייססאיד		TT.TVTVWK	TSCLDV	TRVICCONT			CWITCFHCDS	SAMON WORKING	AGVALKTLDPKI	מייחפרוע קרים.
(1)	1.11	UTITAT V	IIIDI DOMI.			10011 1		DOAMINIDIO		IOWIIODI	DAT TWOOAIAAL		
		)		250		260		280		300	310	320	33
												EALFKKSAETL	
												EALFKKSAETL	
												EALFKKSAETL	
												 EALFKKSAETL	
movo (+12 mov/⊑ //	-)										VKININGEEP	EALFKKSAETL	WINTOKDT T
o V2-2 (113	3) NT	HKOVIOS	AYEIIKLK	GYTSWAI	GLSVMDL	VGSILK	NLRRVHPVS'	TMVKGLYGTK	EELFLSIPC	VLGRNGVSDV	VKINLNSEEF	EALFKKSAETL	WNIOKDLI
								ts of variar					-
(1)		10	2	0	(a) Se	quence	alignment	ts of variar _60	nts in huma	<b>in</b> _80	,90	,100	11-
ULL (1) I	ISTV	KEQLIQNI	_2 APDEKQSR	0 CKITVVGV	(a) Se	quence 40	alignmen 50 GLADELALVD	ts of variar 60 ADENKLKGEA:	nts in huma 70 LDLLHGSLFL	n _80 STPKIVFGKDY	90 SVSANSKLVII	,100 ITAGARMVSGES	11. GRLALLQRN
ULL (1)n tV1 (1)	ASTVI ASTVI	KEQLIQNI KEQLIQNI	_2 "APDEKQSR "APDEKQSR	0 CKITVVGV CKITVVGV	(a) Se	quence 40 AISILLK	s alignmen 50 GLADELALVD GLADELALVD	ts of variar 60 ADENKLKGEA: ADENKLKGEA:	ts in huma 70 LDLLHGSLFL LDLLHGSLFL	IN 80 STPKIVFGKDY STPKIVFGKDY	90 SVSANSKLVII	100 ITAGARMVSGE: ITAGARMVSGE:	114 GRLALLQRNV GRLALLQRNV
ULL (1) n t V1 (1) n t V4 (1) n /3-1 (1) n	MSTVI MSTVI MSTVI MSTVI	KEQLIQNI KEQLIQNI KEQLIQNI KEQLIQNI	2 APDEKQSR APDEKQSR APDEKQSR APDEKQSR	0 CKITVVGV CKITVVGV CKITVVGV CKITVVGV	(a) Se 30 GNVGMAC2 GNVGMAC2 GNVGMAC2 GNVGMAC2	quence 40 AISILLK AISILLK AISILLK AISILLK	50 GLADELALVD GLADELALVD GLADELALVD GLADELALVD	ts of variar 60 ADENKLKGEA ADENKLKGEA ADENKLKGEA	ts in huma 70 LDLLHGSLFL LDLLHGSLFL LDLLHGSLFL LDLLHGSLFL	n STPKIVFGKDY STPKIVFGKDY STPKIVFGK STPKIVFGKET	_90 SVSANSKLVII SVSANSKLVII 	,100 ITAGARMVSGES ITAGARMVSGES REPAVVGAEN	11: SRLALLQRNV SRLALLQRNV
ULL (1) n t V1 (1) n t V4 (1) n /3-1 (1) n t V5 (1) n	ASTVI ASTVI ASTVI ASTVI ASTVI	KEQLIQNI KEQLIQNI KEQLIQNI KEQLIQNI KEQLIQNI	2 "APDEKQSR "APDEKQSR "APDEKQSR "APDEKQSR "APDEKQSR	0 CKITVVGV CKITVVGV CKITVVGV CKITVVGV CKITVVGV	(a) Se 30 GNVGMAC2 GNVGMAC2 GNVGMAC2 GNVGMAC2 GNVGMAC2	40 40 AISILLK AISILLK AISILLK AISILLK	50 GLADELALVD GLADELALVD GLADELALVD GLADELALVD GLADELALVD GLADELALVD	ts of variar 60 ADENKLKGEA ADENKLKGEA ADENKLKGEA ADENKLKGEA	ts in huma 70 LDLLHGSLFL LDLLHGSLFL LDLLHGSLFL LDLLHGSLFL	NN STPKIVFGKDY STPKIVFGKDY STPKIVFGKET STPKIVFGKET STPVCPYGVV	90 SVSANSKLVII SVSANSKLVII KGMESPGSEVH	,100 ITAGARMVSGES ITAGARMVSGES REPAVVGAEN	11: SRLALLQRN SRLALLQRN
ULL (1) n t V1 (1) n t V4 (1) n /3-1 (1) n t V5 (1) n t V6 (1) n	ASTVI ASTVI ASTVI ASTVI ASTVI ASTVI	KEQLIQNI KEQLIQNI KEQLIQNI KEQLIQNI KEQLIQNI KEQLIQNI	2 APDEKQSR APDEKQSR APDEKQSR APDEKQSR APDEKQSR APDEKQSR	0 CKITVVGV CKITVVGV CKITVVGV CKITVVGV CKITVVGV CKITVVGV	(a) Se 30 GNVGMAC2 GNVGMAC2 GNVGMAC2 GNVGMAC2 GNVGMAC2 GNVGMAC2 GNVGMAC2	40 AISILLK AISILLK AISILLK AISILLK AISILLK AISILLK	GLADELALVD GLADELALVD GLADELALVD GLADELALVD GLADELALVD GLADELALVD GLADELALVD	ts of variar 60 ADENKLKGEA ADENKLKGEA ADENKLKGEA ADENKLKGEA ADENKLKGEA	ts in huma 70 LDLLHGSLFL LDLLHGSLFL LDLLHGSLFL LDLLHGSLFL LDLLHGSPFL	80 STPKIVFGKDY STPKIVFGKDY STPKIVFGK STPKIVFGKET STPVCPYGVV STPKIVFGKDY	.90 SVSANSKLVI SVSANSKLVI KGMESPGSEVH	,100 ITAGARMVSGES ITAGARMVSGES REPAVVGAEN	11. SRLALLQRNV SRLALLQRNV
JLL (1) I V1 (1) I V4 (1) I /3-1 (1) I V5 (1) I V5 (1) I V6 (1) I /3-2 (1)	ASTVI ASTVI ASTVI ASTVI ASTVI ASTVI	KEQLIQNI KEQLIQNI KEQLIQNI KEQLIQNI KEQLIQNI	,2 APDEKQSR APDEKQSR APDEKQSR APDEKQSR APDEKQSR APDEKQSR	0 CKITVVGV CKITVVGV CKITVVGV CKITVVGV CKITVVGV CKITVVGV	(a) Se 30 GNVGMAC2 GNVGMAC2 GNVGMAC2 GNVGMAC2 GNVGMAC2 GNVGMAC2 GNVGMAC2 GNVGMAC2	40 AISILLK AISILLK AISILLK AISILLK AISILLK AISILLK AISISLK	50 GLADELALVD GLADELALVD GLADELALVD GLADELALVD GLADELALVD GLADELALVD GLADELALVD	60 ADENKLKGEA ADENKLKGEA ADENKLKGEA ADENKLKGEA ADENKLKGEA ADENKLKGEA ADENKLKGEA	ts in huma 70 LDLLHGSLFL LDLLHGSLFL LDLLHGSLFL LDLLHGSLFL LDLLHGSPFL LGSOOLWUR	80 STPKIVFGKDY STPKIVFGKDY STPKIVFGKET STPKIVFGKET STPKIVFGKDY STPKIVFGKDY FELGFILKSW	90 SVSANSKLVII SVSANSKLVII KGMESPGSEVH  SVSAN SVSAN	100 ITAGARMVSGES ITAGARMVSGES REPAVVGAEN	114 SRLALLQRNV SRLALLQRNV SRLALLQRNV
JLL         (1) I           V1         (1) I           V4         (1) I           '3-1         (1) I           V5         (1) I           V6         (1) I           '3-2         (1) I	ASTVI ASTVI ASTVI ASTVI ASTVI ASTVI	KEQLIQNI KEQLIQNI KEQLIQNI KEQLIQNI KEQLIQNI	,2 APDEKQSR APDEKQSR APDEKQSR APDEKQSR APDEKQSR APDEKQSR	0 CKITVVGV CKITVVGV CKITVVGV CKITVVGV CKITVVGV CKITVVGV	(a) Se 30 GNVGMAC2 GNVGMAC2 GNVGMAC2 GNVGMAC2 GNVGMAC2 GNVGMAC2 GNVGMAC2 GNVGMAC2	40 AISILLK AISILLK AISILLK AISILLK AISILLK AISILLK AISISLK	50 GLADELALVD GLADELALVD GLADELALVD GLADELALVD GLADELALVD GLADELALVD GLADELALVD	60 ADENKLKGEA ADENKLKGEA ADENKLKGEA ADENKLKGEA ADENKLKGEA ADENKLKGEA ADENKLKGEA	ts in huma 70 LDLLHGSLFL LDLLHGSLFL LDLLHGSLFL LDLLHGSLFL LDLLHGSPFL LGSOOLWUR	80 STPKIVFGKDY STPKIVFGKDY STPKIVFGKET STPKIVFGKET STPKIVFGKDY STPKIVFGKDY FELGFILKSW	90 SVSANSKLVII SVSANSKLVII KGMESPGSEVH  SVSAN SVSAN	,100 ITAGARMVSGES ITAGARMVSGES REPAVVGAEN	114 SRLALLQRNV SRLALLQRNV SRLALLQRNV
LL (1) $r$ $\sqrt{1}$ (1) $r$ $\sqrt{4}$ (1) $r$ $\sqrt{4}$ (1) $r$ $\sqrt{5}$ (1) $r$ $\sqrt{5}$ (1) $r$ $\sqrt{6}$ (1) $r$ $\sqrt{2}$ (1) $-$ $\sqrt{2}$ (1) $-$	ASTVI ASTVI ASTVI ASTVI ASTVI ASTVI ASTVI	KEQLIQNI KEQLIQNI KEQLIQNI KEQLIQNI KEQLIQNI KEQLIQNI	2 APDEKQSR APDEKQSR APDEKQSR APDEKQSR APDEKQSR 	0 CKITVVGV CKITVVGV CKITVVGV CKITVVGV CKITVVGV  140	(a) Sec 30 GNVGMAC2 GNVGMAC2 GNVGMAC2 GNVGMAC2 GNVGMAC2 GNVGMAC2 1	40 AISILLK AISILLK AISILLK AISILLK AISILLK AISILLK MAAFSS	GLADELALVD GLADELALVD GLADELALVD GLADELALVD GLADELALVD GLADELALVD GLADELALVD ALQKSSLEKR  160	ts of variar 60 ADENKLKGEA ADENKLKGEA ADENKLKGEA ADENKLKGEA ADENKLKGEA <u>PKAWNPLDLK</u> 170	ts in huma ,70 LDLLHGSLFL LDLLHGSLFL LDLLHGSLFL LDLLHGSLFL LDLLHGSPFL LGSQQLWVLR ,180	80 STPKIVFGKDY STPKIVFGKDY STPKIVFGKT STPKIVFGKDY FELGFILKSTY 190	90 SVSANSKLVI SVSANSKLVI KGMESPGSEVH SVSAN SVSANSKLVI SVSANSKLVI	_100 ITAGARMVSGES ITAGARMVSGES REPAVVGAEN ITAGARMVSGES 210	114 SRLALLQRM SRLALLQRN SRLALLQRN SRLALLQRN 22
LL (1) $r$ V1 (1) $r$ V4 (1) $r$ V4 (1) $r$ V5 (1) $r$ V6 (1) $r$ V6 (1) $r$ V2 (1) $\cdot$ (115) $\underline{1}$ L (115) $T$	MSTVI MSTVI MSTVI MSTVI MSTVI MSTVI 15 15	KEQLIQNI KEQLIQNI KEQLIQNI KEQLIQNI KEQLIQNI KEQLIQNI 120 IVPGVIQI		0 CKITVVGV CKITVVGV CKITVVGV CKITVVGV CKITVVGV  140 IVTNPVDIJ	(a) Sec 30 GNVGMAC2 GNVGMAC2 GNVGMAC2 GNVGMAC2 GNVGMAC2 GNVGMAC2  1 LTYVVWK1	40 AISILLK AISILLK AISILLK AISILLK AISILLK AISILLK MAAFSS 50 SGLPVS	GLADELALVD GLADELALVD GLADELALVD GLADELALVD GLADELALVD GLADELALVD GLADELALVD ALQKSSLEKR  160 SVIGSGCNLD	ts of variar 60 ADENKLKGEA ADENKLKGEA ADENKLKGEA ADENKLKGEA ADENKLKGEA <u>PKAWNPLDLK</u> 170 SARFRYLIGE	ts in huma ,70 LDLLHGSLFL LDLLHGSLFL LDLLHGSLFL LDLLHGSLFL LDLLHGSPFL LGSQQLWVLR ,180 KLGVNPSSCH	80 STPKIVFGKDY STPKIVFGKDY STPKIVFGKET STPVCPYGVV STPKIVFGKDY FELGFILKSTY 190 GWVLGEHGDS:	_90 SVSANSKLVI SVSANSKLVI KGMESPGSEVH SVSAN SVSANSKLVI SVSANSKLVI SVPIWSGVNIA	_100 ITAGARMVSGES ITAGARMVSGES REPAVVGAEN ITAGARMVSGES 210 GVTLKSLNPAI	11: SRLALLQRN SRLALLQRN SRLALLQRN SRLALLQRN COPDSDKEQV
$\begin{array}{c} \text{ILL} & (1) \\ \text{V1} & (1) \\ \text{V1} & (1) \\ \text{V4} & (1) \\ \text{V4} & (1) \\ \text{V3} & (1) \\ \text{V5} & (1) \\ \text{V5} & (1) \\ \text{V6} & (1) \\ \text{V6} & (1) \\ \text{V2} & (1) \\ \text{V2} & (1) \\ \text{V2} & (1) \\ \text{V1} \\ $	ISTVI ISTVI ISTVI ISTVI ISTVI ISTVI ISTVI ISTVI ISTVI ISTVI IMKA	KEQLIQNI KEQLIQNI KEQLIQNI KEQLIQNI KEQLIQNI KEQLIQNI 120 IVPGVIQI IVPGVIQI	2 APDEKQSR APDEKQSR APDEKQSR APDEKQSR APDEKQSR APDEKQSR APDEKQSR APDEKQSR APDEKQSR APDEKQSR APDEKQSR APDEKQSR APDEKIM	0 CKITVVGV CKITVVGV CKITVVGV CKITVVGV CKITVVGV  140 IVTNPVDIJ IVTNPVDIJ	(a) Sec 30 GNVGMAC2 GNVGMAC2 GNVGMAC2 GNVGMAC2 GNVGMAC2 GNVGMAC2  1 LTYVVWK1	40 AISILLK AISILLK AISILLK AISILLK AISILLK MAAFSS 	s alignment 50 GLADELALVD GLADELALVD GLADELALVD GLADELALVD GLADELALVD GLADELALVD ALQKSSLEKR  160 SVIGSGCNLD	ts of variar 60 ADENKLKGEA ADENKLKGEA ADENKLKGEA ADENKLKGEA ADENKLKGEA ADENKLKGEA <u>PKAWNPLDLK</u> 170 SARFRYLIGE	ts in huma ,70 LDLLHGSLFL LDLLHGSLFL LDLLHGSLFL LDLLHGSLFL LDLLHGSPFL LGSQQLWVLR ,180 KLGVNPSSCH	80 STPKIVFGKDY STPKIVFGKDY STPKIVFGKET STPVCPYGVV STPKIVFGKDY FELGFILKSTY 190 GWVLGEHGDS:	90 SVSANSKLVI SVSANSKLVI KGMESPGSEVH SVSAN SVSANSKLVI SVSANSKLVI SVPIWSGVNIA PIWSGVNIA	_100 ITAGARMVSGES ITAGARMVSGES REPAVVGAEN ITAGARMVSGES 210 GVTLKSLNPAI GVTLKSLNPAI	11: GRLALLQRN GRLALLQRN GRLALLQRN GPDSDKEQI GSDSDKEQI
$\begin{array}{c} \text{ILL} & (1) \\ \text{V1} & (1) \\ \text{V1} & (1) \\ \text{V4} & (1) \\ \text{V4} & (1) \\ \text{V3} & (1) \\ \text{V5} & (1) \\ \text{V5} & (1) \\ \text{V6} & (1) \\ \text{V6} & (1) \\ \text{V2} & (1) \\ \text{V2} & (1) \\ \text{V2} & (1) \\ \text{V1} \\ $	ISTVI ISTVI ISTVI ISTVI ISTVI ISTVI ISTVI ISTVI ISTVI ISTVI IMKA	KEQLIQNI KEQLIQNI KEQLIQNI KEQLIQNI KEQLIQNI KEQLIQNI 120 IVPGVIQI IVPGVIQI	2 APDEKQSR APDEKQSR APDEKQSR APDEKQSR APDEKQSR APDEKQSR APDEKQSR APDEKQSR APDEKQSR APDEKQSR APDEKQSR APDEKQSR APDEKIM	0 CKITVVGV CKITVVGV CKITVVGV CKITVVGV CKITVVGV  140 IVTNPVDIJ IVTNPVDIJ	(a) Sec 30 GNVGMAC2 GNVGMAC2 GNVGMAC2 GNVGMAC2 GNVGMAC2 GNVGMAC2  1 LTYVVWK1	40 AISILLK AISILLK AISILLK AISILLK AISILLK MAAFSS 	s alignment 50 GLADELALVD GLADELALVD GLADELALVD GLADELALVD GLADELALVD GLADELALVD ALQKSSLEKR  160 SVIGSGCNLD	ts of variar 60 ADENKLKGEA ADENKLKGEA ADENKLKGEA ADENKLKGEA ADENKLKGEA ADENKLKGEA <u>PKAWNPLDLK</u> 170 SARFRYLIGE	ts in huma ,70 LDLLHGSLFL LDLLHGSLFL LDLLHGSLFL LDLLHGSLFL LDLLHGSPFL LGSQQLWVLR ,180 KLGVNPSSCH	80 STPKIVFGKDY STPKIVFGKDY STPKIVFGKET STPVCPYGVV STPKIVFGKDY FELGFILKSTY 190 GWVLGEHGDS:	90 SVSANSKLVI SVSANSKLVI KGMESPGSEVH SVSAN SVSANSKLVI SVSANSKLVI SVPIWSGVNIA PIWSGVNIA	_100 ITAGARMVSGES ITAGARMVSGES REPAVVGAEN ITAGARMVSGES 210 GVTLKSLNPAI	11: GRLALLQRN GRLALLQRN GRLALLQRN GPDSDKEQI GSDSDKEQI
LL (1) $\Gamma$ V1 (1) $\Gamma$ V4 (1) $\Gamma$ 3-1 (1) $\Gamma$ V5 (1) $\Gamma$ V5 (1) $\Gamma$ V2 (1) - V2 (1) - (115) $\underline{\Gamma}$ L (115) $T$ 14 (82) -	ASTVI ASTVI ASTVI ASTVI ASTVI ASTVI ASTVI INKA IMKA	KEQLIQNI KEQLIQNI KEQLIQNI KEQLIQNI KEQLIQNI KEQLIQNI 120 IVPGVIQ IVPGVIQ	2 APDEKQSR APDEKQSR APDEKQSR APDEKQSR APDEKQSR 130 NSPDCKIM. NSPDCKIM.	0 CKITVVGV CKITVVGV CKITVVGV CKITVVGV CKITVVGV CKITVVGV 	(a) Se 30 GNVGMAC2 GNVGMAC2 GNVGMAC2 GNVGMAC2 GNVGMAC2 GNVGMAC2 	40 AISILLK AISILLK AISILLK AISILLK AISILLK AISILLK MAAFSS 	s alignment 50 GLADELALVD GLADELALVD GLADELALVD GLADELALVD GLADELALVD GLADELALVD GLADELALVD SVIGSSCNLD	ts of variar 60 ADENKLKGEA ADENKLKGEA ADENKLKGEA ADENKLKGEA ADENKLKGEA <u>ADENKLKGEA</u> <u>PKAWNPLDLK</u> 170 SARFRYLIGE	ts in huma 70 LDLLHGSLFL LDLLHGSLFL LDLLHGSLFL LDLLHGSLFL LDLLHGSPFL LGSQQLWVLR 180 KLGVNPSSCH	80 STPKIVFGKDY STPKIVFGKDY STPKIVFGKET STPKIVFGKDY STPKIVFGKDY FELGFILKSY 190 GWVLGEHGDS:	90 SVSANSKLVI SVSANSKLVI KGMESPGSEVH SVSAN SVSANSKLVI 200 SVPIWSGVNIA PIWSGVNIA -VPIWSGVNIA	_100 ITAGARMVSGES ITAGARMVSGES REPAVVGAEN ITAGARMVSGES 210 GVTLKSLNPAI GVTLKSLNPAI	11: GRLALLQRN GRLALLQRN GRLALLQRN C GPDSDKEQV GSDSDKEQV GSDSDKEQV
$\begin{array}{c} \text{ILL} & (1) \\ \text{V1} & (1) \\ \text{V4} & (1) \\ \text{V4} & (1) \\ \text{V4} & (1) \\ \text{V4} & (1) \\ \text{V5} & (1) \\ \text{V5} & (1) \\ \text{V6} & (1) \\ \text{V6} & (1) \\ \text{V2} & (1) \\ \text{V2} & (1) \\ \text{V2} & (1) \\ \text{V2} & (1) \\ \text{V3} & (115) \\ \text{T} \\ \text{V1} & (115) \\ \text{T} \\ \text{V1} & (115) \\ \text{T} \\ \text{V2} & (1) \\ \text{V2} & (1) \\ \text{V2} & (1) \\ \text{V3} & (1) \\ \text{V2} & (1) \\ \text{V3} & (1) \\ \text{V4} & (1) \\ \text{V4} & (1) \\ \text{V4} & (1) \\ \text{V4} & (1) \\ \text{V6} & (1) \\ \text{V6} & (1) \\ \text{V7} & ($	4STVI 4STVI 4STVI 4STVI 4STVI 4STVI 15 1MKA 1MKA 	KEQLIQNI KEQLIQNI KEQLIQNI KEQLIQNI KEQLIQNI KEQLIQNI IVPGVIQI IVPGVIQI	2 APDEKQSR APDEKQSR APDEKQSR APDEKQSR APDEKQSR 130 NSPDCKIM NSPDCKIM	0 CKITVVGV CKITVVGV CKITVVGV CKITVVGV CKITVVGV CKITVVGV 140 IVTNPVDIJ IVTNPV	(a) Se	40 AISILLK AISILLK AISILLK AISILLK AISILLK AISILLK MAAFSS 	s alignmeni 50 GLADELALVD GLADELALVD GLADELALVD GLADELALVD GLADELALVD GLADELALVD GLADELALVD SVIGSSCNLD SVIGSGCNLD	ts of variar 60 ADENKLKGEA ADENKLKGEA ADENKLKGEA ADENKLKGEA ADENKLKGEA PKAWNPLDLK 170 SARFRYLIGE 	ts in huma 70 LDLLHGSLFL LDLLHGSLFL LDLLHGSLFL LDLLHGSLFL LDLLHGSLFL LDLLHGSPFL LGSQQLWVLR 180 KLGVNPSSCH	80 STPKIVFGKDY STPKIVFGKDY STPKIVFGKET STPKVFGKDY STPKIVFGKDY FELGFILKSNY 190 GWVLGEHGDS:	90 SVSANSKLVI SVSANSKLVI KGMESPGSEVH SVSAN SVSANSKLVI 200 SVPIWSGVNIA PIWSGVNIA PIWSGVNIA	100 ITAGARMVSGES ITAGARMVSGES REPAVVGAEN ITAGARMVSGES 210 GVTLKSLNPAT GVTLKSLNPAT GVTLKSLNPAT	11: GRLALLQRN GRLALLQRN GRLALLQRN C GPDSDKEQV GSDSDKEQV GSDSDKEQV
$\begin{array}{c} \text{JLL} (1) \\ \text{V1} (1) \\ \text{V1} (1) \\ \text{V4} (1) \\ \text{V4} (1) \\ \text{V4} (1) \\ \text{V5} (1) \\ \text{V5} (1) \\ \text{V6} (1) \\ \text{V6} (1) \\ \text{V2} (1) \\ \text{V3} \\ \text{V2} (1) \\ \text{V4} (115) \\ \text{T} \\ \text{V4} (82) \\ \text{-1} (104) \\ \text{-1} \\ \text{V5} (83) \\ \text{-1} \\ \text{V6} (89) \\ \text{-1} \end{array}$	ASTVI ASTVI ASTVI ASTVI ASTVI ASTVI INKA IMKA	KEQLIQNI KEQLIQNI KEQLIQNI KEQLIQNI KEQLIQNI KEQLIQNI IVPGVIQI IVPGVIQI IVPGVIQI	2 APDEKQSR APDEKQSR APDEKQSR APDEKQSR APDEKQSR 130 NSPDCKIM NSPDCKIM	0 CKITVVGV CKITVVGV CKITVVGV CKITVVGV CKITVVGV CKITVVGV 140 IVTNPVDIJ IVTNPVDIJ	(a) Se	40 AISILLK AISILLK AISILLK AISILLK AISILLK AISILLK 50 SGLPVS	alignment 50 GLADELALVD GLADELALVD GLADELALVD GLADELALVD GLADELALVD GLADELALVD GLADELALVD SVIGSSCNLD	ts of variar 60 ADENKLKGEA ADENKLKGEA ADENKLKGEA ADENKLKGEA ADENKLKGEA <u>PKAWNPLDLK</u> 170 SARFRYLIGE 	ts in huma 70 LDLLHGSLFL LDLLHGSLFL LDLLHGSLFL LDLLHGSLFL LDLLHGSLFL LDLLHGSPFL LGSQQLWVLR 180 KLGVNPSSCH	80 STPKIVFGKDY STPKIVFGKDY STPKIVFGKET STPKIVFGKDY STPKIVFGKDY FELGFILKSSY 190 GWVLGEHGDS:	90 SVSANSKLVI SVSANSKLVI KGMESPGSEVH SVSAN SVSANSKLVI 200 SVPIWSGVNIA PIWSGVNIA PIWSGVNIA	_100 ITAGARMVSGES ITAGARMVSGES ITAGARMVSGES ITAGARMVSGES 210 GVTLKSLNPAT GVTLKSLNPAT GVTLKSLNPAT	11: SRLALLQRN SRLALLQRN SRLALLQRN C SRLALL SRLAL
$\begin{array}{c} \text{JLL} (1) \\ \text{(1)} \\ \text{(1)} \\ \text{(1)} \\ \text{(1)} \\ \text{(2)} \\ \text{(1)} \\ \text{(2)} \\ \text$	4STVI 4STVI 4STVI 4STVI 4STVI 4STVI 15 15 1MKA 1MKA  1MKA	KEQLIQNI KEQLIQNI KEQLIQNI KEQLIQNI KEQLIQNI KEQLIQNI IVPGVIQI IVPGVIQI IVPGVIQI IVPGVIQI	2 APDEKQSR APDEKQSR APDEKQSR APDEKQSR APDEKQSR 130 NSPDCKIM NSPDCKIM	0 CKITVVGV CKITVVGV CKITVVGV CKITVVGV CKITVVGV CKITVVGV 140 IVTNPVDII IVTNPVDII	(a) Se	40 AISILLK AISILLK AISILLK AISILLK AISILLK AISILLK 50 SGLPVS	alignment 50 GLADELALVD GLADELALVD GLADELALVD GLADELALVD GLADELALVD GLADELALVD GLADELALVD SVIGSSCNLD	ts of variar 60 ADENKLKGEA ADENKLKGEA ADENKLKGEA ADENKLKGEA ADENKLKGEA <u>PKAWNPLDLK</u> 170 SARFRYLIGE 	ts in huma 70 LDLLHGSLFL LDLLHGSLFL LDLLHGSLFL LDLLHGSLFL LDLLHGSLFL LDLLHGSPFL LGSQQLWVLR 180 KLGVNPSSCH	80 STPKIVFGKDY STPKIVFGKDY STPKIVFGKET STPKIVFGKDY STPKIVFGKDY FELGFILKSSY 190 GWVLGEHGDS:	90 SVSANSKLVI SVSANSKLVI KGMESPGSEVH SVSAN SVSANSKLVI 200 SVPIWSGVNIA PIWSGVNIA PIWSGVNIA	100 ITAGARMVSGES ITAGARMVSGES REPAVVGAEN ITAGARMVSGES 210 GVTLKSLNPAI GVTLKSLNPAI GVTLKSLNPAI	11: GRLALLQRN GRLALLQRN GRLALLQRN C GPDSDKEQV GSDSDKEQV GSDSDKEQV GSDSDKEQV GSDSDKEQV
LL (1) $\vec{I}$ V1 (1) $\vec{I}$ V4 (1) $\vec{I}$ V4 (1) $\vec{I}$ V5 (1) $\vec{I}$ V5 (1) $\vec{I}$ V6 (1) $\vec{I}$ V2 (1) $\vec{I}$ (115) $\vec{I}$ (115) $\vec{I}$ (115) $\vec{T}$ 1 (115) $\vec{T}$ 1 (115) $\vec{T}$ 4 (82) $-$ 1 (104) $-$ 5 (83) $-$ 6 (89) $-$ 2 (79) $\vec{T}$	4STVI 4STVI 4STVI 4STVI 4STVI 4STVI 15 15 1MKA 1MKA  1MKA	KEQLIQNI KEQLIQNI KEQLIQNI KEQLIQNI KEQLIQNI KEQLIQNI IVPGVIQI IVPGVIQI IVPGVIQI IVPGVIQI	2 APDEKQSR APDEKQSR APDEKQSR APDEKQSR APDEKQSR 130 NSPDCKIM NSPDCKIM	0 CKITVVGV CKITVVGV CKITVVGV CKITVVGV CKITVVGV CKITVVGV 140 IVTNPVDII IVTNPVDII	(a) Se	40 AISILLK AISILLK AISILLK AISILLK AISILLK AISILLK SO SGLPVS	s alignment 50 GLADELALVD GLADELALVD GLADELALVD GLADELALVD GLADELALVD GLADELALVD SVIGSGCNLD SVIGSGCNLD	ts of variar 60 ADENKLKGEA ADENKLKGEA ADENKLKGEA ADENKLKGEA ADENKLKGEA <u>PKAWNPLDLK</u> 170 SARFRYLIGE 	ts in huma 70 LDLLHGSLFL LDLLHGSLFL LDLLHGSLFL LDLLHGSLFL LDLLHGSPFL LGSQQLWVLR 180 KLGVNPSSCH	80 STPKIVFGKDY STPKIVFGKDY STPKIVFGKET STPKIVFGKDY STPKIVFGKDY FELGFILKSSY 190 GWVLGEHGDS:	90 SVSANSKLVI SVSANSKLVI KGMESPGSEVH SVSAN SVSANSKLVI 200 SVPIWSGVNIA PIWSGVNIA PIWSGVNIA	100 ITAGARMVSGES ITAGARMVSGES REPAVVGAEN ITAGARMVSGES 210 GVTLKSLNPAI GVTLKSLNPAI GVTLKSLNPAI	11: SRLALLQRNV SRLALLQRNV SRLALLQRNV SRLALLQRNV CSDSDKEQW GSDSDKEQW GSDSDKEQW GSDSDKEQW
$\begin{array}{c} \text{ILL} (1) \ 1 \\ \text{V1} (1) \ 1 \\ \text{V4} (1) \ 1 \\ \text{3-1} (1) \ 1 \\ \text{V5} (1) \ 1 \\ \text{V5} (1) \ 1 \\ \text{V6} (1) \ 1 \\ \text{3-2} (1) \\ \text{V2} (1) \\ \text{V3} \\ \text{V4} (15) \ 1 \\ \text{V7} \\ \text{V6} \\ \text{V6} \\ \text{V7} \\ \text{V7} \\ \text{V7} \\ \text{V7} \\ \text{V8} \\ \text{V8} \\ \text{V7} \\ \text{V8} \\ \text{V8} \\ \text{V8} \\ \text{V8} \\ \text{V8} \\ \text{V9} \\ \text{V9} \\ \text{V9} \\ \text{V9} \\ \text{V9} \\ \text{V9} \\ \text{V1} \\$	4STVI 4STVI 4STVI 4STVI 4STVI 4STVI 15 15 1MKA  1MKA 	KEQLIQNI KEQLIQNI KEQLIQNI KEQLIQNI KEQLIQNI KEQLIQNI IVPGVIQI IVPGVIQI IVPGVIQI IVPGVIQI	2 APDEKQSR APDEKQSR APDEKQSR APDEKQSR APDEKQSR 130 NSPDCKIM NSPDCKIM	0 CKITVVGV CKITVVGV CKITVVGV CKITVVGV CKITVVGV CKITVVGV 140 IVTNPVDII IVTNPVDII	(a) Se	40 AISILLK AISILLK AISILLK AISILLK AISILLK AISILLK SO SGLPVS	s alignment 50 GLADELALVD GLADELALVD GLADELALVD GLADELALVD GLADELALVD GLADELALVD SVIGSGCNLD SVIGSGCNLD	ts of variar 60 ADENKLKGEA ADENKLKGEA ADENKLKGEA ADENKLKGEA ADENKLKGEA <u>ADENKLKGEA</u> <u>ADENKLKGEA</u> <u>ADENKLKGEA</u> <u>DENKLKGEA</u> <u>ADENKLKGEA</u> <u>ADENKLKGEA</u> <u>ADENKLKGEA</u> <u>ADENKLKGEA</u> <u>ADENKLKGEA</u> <u>ADENKLKGEA</u> <u>ADENKLKGEA</u> <u>ADENKLKGEA</u> <u>ADENKLKGEA</u> <u>ADENKLKGEA</u> <u>ADENKLKGEA</u> <u>ADENKLKGEA</u> <u>ADENKLKGEA</u> <u>ADENKLKGEA</u> <u>ADENKLKGEA</u> <u>ADENKLKGEA</u> <u>ADENKLKGEA</u> <u>ADENKLKGEA</u>	ts in huma 70 LDLLHGSLFL LDLLHGSLFL LDLLHGSLFL LDLLHGSLFL LDLLHGSPFL LGSQQLWVLR 180 KLGVNPSSCH	80 STPKIVFGKDY STPKIVFGKDY STPKIVFGKET STPKIVFGKDY STPKIVFGKDY FELGFILKSSY 190 GWVLGEHGDS:	90 SVSANSKLVI SVSANSKLVI KGMESPGSEVH SVSANSKLVI SVSANSKLVI 200 SVPIWSGVNIA PIWSGVNIA PIWSGVNIA	100 ITAGARMVSGES ITAGARMVSGES REPAVVGAEN ITAGARMVSGES 210 GVTLKSLNPAI GVTLKSLNPAI GVTLKSLNPAI	11: GRLALLQRN GRLALLQRN GRLALLQRN C GPDSDKEQV GSDSDKEQV GSDSDKEQV GSDSDKEQV MNPDKEQV
$\begin{array}{c} \text{JLL} (1) \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \$	4STVI 4STVI 4STVI 4STVI 4STVI 4STVI 4STVI 15 1MKA 1MKA 1MKA 1MKA 2229 TVHI	KEQLIQNI KEQLIQNI KEQLIQNI KEQLIQNI KEQLIQNI KEQLIQNI IVPGVIQI IVPGVIQI IVPGVIQI IVPGVIQI	2 APDEKQSR APDEKQSR APDEKQSR APDEKQSR APDEKQSR APDEKQSR APDEKUSR APD	0 CKITVVGV CKITVVGV CKITVVGV CKITVVGV CKITVVGV 140 IVTNPVDII IVTNPVDII IVTNPVDII IVTNPVDII IVTNPVDII IVTNPVDII 250 YTSWAIA	(a) Se	40 AISILLK AISILLK AISILLK AISILLK AISILLK 50 SGLPVS SGLPVS SGLPVS 60 ASILKN	s alignmeni 50 GLADELALVD GLADELALVD GLADELALVD GLADELALVD GLADELALVD GLADELALVD GLADELALVD ALQKSSLEKR 160 SVIGSGCNLD SVIGSGCNLD SVIGSGCNLD SVIGSGCNLD 270 LKRVHAVTT	ts of variar 60 ADENKLKGEA ADENKLKGEA ADENKLKGEA ADENKLKGEA ADENKLKGEA PKAWNPLDLK 170 SARFRYLIGE  SARFRYLIGE  SARFRYLIGE 280 LVKGLYGIKH	ts in huma 70 LDLLHGSLFL LDLLHGSLFL LDLLHGSLFL LDLLHGSLFL LDLLHGSLFL LDLLHGSLFL LDLLHGSPFL 180 KLGVNPSSCH 	80 STPKIVFGKDY STPKIVFGKDY STPKIVFGKF STPKIVFGKDY STPKIVFGKDY PELGFILKSY 190 GWVLGEHGDS: GWVLGEHGDS: GWVLGEHGDS: 300 'LGQSGITDLY	90 SVSANSKLVI SVSANSKLVI KGMESPGSEVH SVSAN SVSANSKLVI 200 SVPIWSGVNIA PIWSGVNIA PIWSGVNIA SVPIWSGVNIA SVPIWSGVNIA 	_100 ITAGARMVSGES ITAGARMVSGES REPAVVGAEN ITAGARMVSGES 	11: SRLALLQRN SRLALLQRN SRLALLQRN SRLALLQRN 2: GPDSDKEQU GSDSDKEQU GSDSDKEQU GSDSDKEQU GSDSDKEQU MPDKEQU 33: WNIQKDLQI
$\begin{array}{c} \text{JLL} (1) \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \$	4STVI 4STVI 4STVI 4STVI 4STVI 4STVI 15 15 1MKA 1MKA  1MKA  229 TVHI TVHI	KEQLIQNI KEQLIQNI KEQLIQNI KEQLIQNI KEQLIQNI KEQLIQNI IVPGVIQ IVPGVIQ IVPGVIQ IVPGVIQ KQVVDGG KQVVDGG	2	0 CKITVVGV CKITVVGV CKITVVGV CKITVVGV CKITVVGV CKITVVGV 140 IVTNPVDII IVTNPVDII IVTNPVDII IVTNPVDII IVTNPVDII SYTSWAIA	(a) Se	40 AISILLK AISILLK AISILLK AISILLK AISILLK MAAFSS 50 SGLPVS SGLPVS 60 ASILKN	s alignmeni 50 GLADELALVD GLADELALVD GLADELALVD GLADELALVD GLADELALVD GLADELALVD GLADELALVD GLADELALVD ALQKSSLEKR 	ts of variar 60 ADENKLKGEA ADENKLKGEA ADENKLKGEA ADENKLKGEA ADENKLKGEA ADENKLKGEA <u>ADENKLKGEA</u> <u>ADENKLKGEA</u> <u>DKAWNPLDLK</u>      SARFRYLIGE     SARFRYLIGE   	ts in huma 70 LDLLHGSLFL LDLLHGSLFL LDLLHGSLFL LDLLHGSLFL LDLLHGSLFL LDLLHGSPFL LGSQQLWVLR 180 KLGVNPSSCH 	80 STPKIVFGKDY STPKIVFGKDY STPKIVFGKT STPKIVFGKDY STPKIVFGKDY FELGFILKSTY [190 GWVLGEHGDS: GWVLGEHGDS: GWVLGEHGDS: 300 LGQSGITDLY LGQSGITDLY	_90 SVSANSKLVII SVSANSKLVII SVSANSKLVII SVSAN SVSANSKLVII 200 SVPIWSGVNIA PIWSGVNIA PIWSGVNIA SVPIWSGVNIA 310 /KVNMNTEEE	_100 ITAGARMVSGES ITAGARMVSGES REPAVVGAEN ITAGARMVSGES 210 GVTLKSLNPAI GVTLKSLNPAI GVTLKSLNPAI GVTLKSLNPAI GVTLKSLNPAI	11: SRLALLQRNV SRLALLQRNV SRLALLQRNV SRLALLQRNV 22 GPDSDKEQV GSDSDKEQV GSDSDKEQV GSDSDKEQV GSDSDKEQV MPDKEQV 333 WNIQKDLQI
$\begin{array}{c} \text{JLL} (1) \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \$	4STVI 4STVI 4STVI 4STVI 4STVI 4STVI 15 15 1MKA  1MKA  1MKA  229 TVHI TVHI	KEQLIQNI KEQLIQNI KEQLIQNI KEQLIQNI KEQLIQNI IVPGVIQ IVPGVIQ IVPGVIQ IVPGVIQ IVPGVIQ COVVDGG COVVDGG COVVDGG	2	0 CKITVVGV CKITVVGV CKITVVGV CKITVVGV CKITVVGV CKITVVGV 140 IVTNPVDII IVTNPVDII IVTNPVDII 	(a) Se 30 GNVGMAC2 GNVGMAC2 GNVGMAC2 GNVGMAC2 GNVGMAC2 GNVGMAC2 GNVGMAC2 GNVGMAC2 LIVVGMAC2 LIVVGMAC2 LIVVGMAC2 LIVVGMAC2 LIVGMAC2	40 AISILLK AISILLK AISILLK AISILLK AISILLK AISISISIK MAAFSS 50 SGLPVS SGLPVS SGLPVS 60 ASILKN ASILKN	alignmeni 50 GLADELALVD GLADELALVD GLADELALVD GLADELALVD GLADELALVD GLADELALVD GLADELALVD ALQKSSLEKR  SVIGSGCNLD  SVIGSGCNLD  270 LKRVHAVTT 	ts of variar 60 ADENKLKGEA ADENKLKGEA ADENKLKGEA ADENKLKGEA ADENKLKGEA DENKLKGEA 170 SARFRYLIGE SARFRYLIGE 280 LVKGLYGIKI LVKGLYGIKI	ts in huma 70 LDLLHGSLFL LDLLHGSLFL LDLLHGSLFL LDLLHGSLFL LDLLHGSLFL LDLLHGSPFL 180 KLGVNPSSCH 290 201 290 201 201 201 201 201 201 201 20	80 STPKIVFGKDY STPKIVFGKDY STPKIVFGKT STPKIVFGKDY STPKIVFGKDY STPKIVFGKDY TELGFILKST 190 GWVLGEHGDS:	90 SVSANSKLVI: SVSANSKLVI: SVSAN SVSANSKLVI: 200 SVPIWSGVNIA PIWSGVNIA PIWSGVNIA SVPIWSGVNIA SVPIWSGVNIA 	_100 ITAGARMVSGES ITAGARMVSGES REPAVVGAEN ITAGARMVSGES 	114 SRLALLQRNV SRLALLQRNV SRLALLQRNV SRLALLQRNV 22 GPDSDKEQW GSDSDKEQW GSDSDKEQW GSDSDKEQW GSDSDKEQW 332 WNIQKDLQI
$\begin{array}{c} \text{ILL} (1) \ \ $	4STVI 4STVI 4STVI 4STVI 4STVI 4STVI 4STVI 15 15 15 1MKA  1MKA  1MKA  1MKA  1MKA  1MKA  1MKA 	KEQLIQNI KEQLIQNI KEQLIQNI KEQLIQNI KEQLIQNI KEQLIQNI IVPGVIQI IVPGVIQI IVPGVIQI IVPGVIQI IVPGVIQI IVPGVIQI IVPGVIQI IVPGVIQI IVPGVIQI IVPGVIQI IVPGVIQI IVPGVIQI IVPGVIQI IVPGVIQI	2 APDEKQSR APDEKQSR APDEKQSR APDEKQSR APDEKQSR 130 NSPDCKIM NSPDCKIM NSPDCKIM NSPDCKIM NSPDCKIM 240 YEVLNLKG	0 CKITVVGV CKITVVGV CKITVVGV CKITVVGV CKITVVGV 140 IVTNPVDIJ IVTNPVDI IVTNPVDI IVTNPVDI IVTNPVDI IVTNPVDI IVTNPVDI IVTNPVDI IVTN	(a) Se	40 AISILLK AISILLK AISILLK AISILLK AISILLK AISILLK SO SGLPVS SGLPVS CO ASILKN ASILKN	2 alignment 50 GLADELALVD GLADELALVD GLADELALVD GLADELALVD GLADELALVD GLADELALVD GLADELALVD GLADELALVD SVIGSGCNLD 	ts of variar <u>60</u> ADENKLKGEA ADEN	ts in huma 70 LDLLHGSLFL LDLLHGSLFL LDLLHGSLFL LDLLHGSLFL LDLLHGSLFL LDLLHGSPFL 100 180 KLGVNPSSCH 290 290 291 EEIFLSIPCV 290	N 80 STPKIVFGKDY STPKIVFGKDY STPKIVFGKDY STPKIVFGKDY STPKIVFGKDY PELGFILKSY 190 GWVLGEHGDS: GWVLGEHGDS: GWVLGEHGDS: 120 GWVLGEHGDS: 120 120 120 120 120 120 120 120	90 SVSANSKLVI SVSANSKLVI SVSANSKLVI SVSAN	_100 IITAGARMVSGES IITAGARMVSGES REPAVVGAEN IITAGARMVSGES 210 GVTLKSLNPAI GVTLKSLNPAI GVTLKSLNPAI GVTLKSLNPAI GVTLKSLNPAI	11: SRLALLQRNV SRLALLQRNV SRLALLQRNV SRLALLQRNV 2: GPDSDKEQW GSDSDKEQW GSDSDKEQW GSDSDKEQW GSDSDKEQW MNIQKDLQI WNIQKDLQI WNIQKDLQI
$\begin{array}{c} \text{JLL} (1) \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \$	4STVI 4STVI 4STVI 4STVI 4STVI 4STVI 4STVI 4STVI 1STVI 1MKA  1MKA  1MKA  229 TVHI TVHI TVHI 	KEQLIQNI KEQLIQNI KEQLIQNI KEQLIQNI KEQLIQNI KEQLIQNI IVPGVIQI IVPGVIQI IVPGVIQI IVPGVIQI IVPGVIQI IVPGVIQI COVVDGG COVVDGG COVVDGG	2 APDEKQSR APDEKQSR APDEKQSR APDEKQSR APDEKQSR APDEKQSR APDEKUSR APD	0 CKITVVGV CKITVVGV CKITVVGV CKITVVGV CKITVVGV (KITVVGV 140 IVTNPVDII IVTNPVDI IVTNPVDI IVTNPVDI IVTNPVDI IVTNPVDI IVTNPVDI IVTNPVDI IVTNP	(a) Se	40 AISILLK AISILLK AISILLK AISILLK AISILLK MAAFSS 50 SGLPVS SGLPVS SGLPVS ASILKN ASILKN	alignmeni 50 GLADELALVD GLADELALVD GLADELALVD GLADELALVD GLADELALVD GLADELALVD GLADELALVD SVIGSGCNLD SVIGSGCNLD SVIGSGCNLD SVIGSGCNLD SVIGSGCNLD SVIGSGCNLD SVIGSGCNLD SVIGSGCNLD	ts of variar <u>60</u> ADENKLKGEA ADENKLKGEA ADENKLKGEA ADENKLKGEA ADENKLKGEA ADENKLKGEA <u>770</u> SARFRYLIGE SARFRYLIGE SARFRYLIGE LVKGLYGIKI	ts in huma 70 LDLLHGSLFL LDLLHGSLFL LDLLHGSLFL LDLLHGSLFL LDLLHGSLFL LDLLHGSLFL LDLLHGSPFL LGSQQLWVLR 180 KLGVNPSSCH 290 EEIFLSIPCV EEIFLSIPCV EEIFLSIPCV	80 STPKIVFGKDY STPKIVFGKDY STPKIVFGKDY STPKIVFGKDY STPKIVFGKDY PLGFILKSY 190 GWVLGEHGDS:	90 SVSANSKLVI SVSANSKLVI SVSANSKLVI SVSAN SVSANSKLVI 200 SVPIWSGVNIA PIWSGVNIA PIWSGVNIA PIWSGVNIA SVPIWSGVNIA SVPIWSGVNIA 	_100 ITAGARMVSGES ITAGARMVSGES REPAVVGAEN ITAGARMVSGES 	11 SRLALLQRN SRLALLQRN SRLALLQRN SRLALLQRN 2 GPDSDKEQU GSDSDKEQU GSDS

# (b) Sequence alignments of variants in rat

Fig. 2: Amino acid sequence alignments of putative polypeptides encoded by splicing variants of human (A) and rat (B). Alignments were set to meet maximum sequences identity, gaps are represented by dashes, and amino acid residues unidentical at N-terminal or C-terminal were indicated by boxes




Fig. 3: Expression analysis by RT-PCR during testis development. A, expression profiles of splicing variants of LDH-C; B, expression profiles of PPIA (housekeeping gene); lane M, DNA maker; lane T1 to T6, testes of 1 week rat to 6 week rat




Fig. 4: Western blotting analysis of LDH-C during testis development. The bands about 34 kDa represented LDH. Lane T1 to T6, testes of 1 week rat to 6 week rat

and variant 2 lacked the partial of exon 2 (70 bp at 3' end) and 6 (72 bp at 5' end), the entire exon 3, 4 and 5; variants 3 was inserted by the partial of intron 3 (91 bp in the middle of intron 3); variant 4 lacked the entire exon 4, 5 and the partial of exon 6 (11 bp at 3' end); variant 5 lacked the partial of exon 3 (19 bp at 3' end), the entire exon 4 and kept the last 3 bp (3' end) of exon 5; variant 6 lacked the partial of exon 4 (154 bp at 3' end) and 8 (87 bp at 5' end), the entire exon 5, 6, 7; The missing of exons lead to the changes of protein structure, some variants (2, 3, 4, 5, 7) lost the entire or partial NAD binding domain, some variants (2, 4, 5, 6, 7) lost the active site and some variants (2, 4, 5, 7) lost both of them, only variant 1 contained both of them. The putative polypeptides (more than 50 amino-acid residues polypeptides were considered) encoded by rat splicing variants were compared with the full length LDH-C protein, the results show that some of these putative polypeptides were truncated LDH-C proteins (polypeptides encoded by variants 1,6) and the others were also truncated proteins with a few amino acid residues at N-terminal (polypeptides encoded by variants 3,4,5) or C-terminal (polypeptides encoded by variants 2,3) different from LDH-C(Fig. 2b).

**RT–PCR analysis of rat LDH-C gene expression:** In order to analysis the expression profile of these variants during testes development, RT-PCR method was

employed. Some of the variants could be detected by primer rps and rpa (Table 1). As shown in Fig. 3a, the bands in 1 kb position (the brightest band in lane T3, T4, T5, T6) reflected the mRNAs with full length ORF. The bands less than 1 kb reflected the variants. From Fig. 3 we can see that the expression of full length mRNA increased with the development of testes, this is in accordance with other reports (Thomas et al., 1990). In 1 and 2 week age testes (T1 & T2), we can hardly see the 1 kb band; instead, there were some other bands less or larger than 1 kb, these bands reflected the splicing variants except the band about 500 bp in lane T1 and T2 (it turns out to be a non-special fragment, not LDH-C variant). In general, the expression levels of some variants are significant during the development of testes (T1 to T6). Figure 3b was the RT-PCR of the housekeeping gene PPIA (peptidylprolyl isomerase A): the amplification fragment was 98 bp which was the expected size.

**Western blot analysis:** In order to detect if the variants were translated into proteins, western blotting were performed. Because primary antibody H-160 were raised against amino acids 173-332 mapping at the C-terminus of LDH-A, the putative polypeptides beside rat V3-1 and V5 have the possibility be detected. The results were displayed in Fig. 4, the band about 34 kDa was LDH and there were no bands below 34 kDa.

#### DISCUSSION

Multiple splicing variants of LDH-C in human and rat normal testes were cloned. The results show that LDH-C is not totally silenced by transcriptional repression as previous reported (Tang et al., 2008; Tang and Goldberg, 2009; Kroft et al., 2003) in non-mature germ cells and somatic cells, but transcripted and alternatively spliced. Alternative splicing is the process by which a single pre-mRNA is spliced in different ways to generate multiple mRNA transcripts. It is thought previously that the alternative splicing variants are translated into proteins. In recent years, it becomes clearly that a substantial fraction of these variants are actually targets of NMD (nonsense-mediated mRNA decay). This process represents an important mechanism for post-transcriptional regulation of gene expression (Lejeune and Maquat, 2005; Lewis et al., 2003). In this study, 5 splicing variants of LDH-C were cloned from human testes and spermatozoa and 6 splicing variants of LDH-C were cloned from rat testes and non-testes tissues. The alternative splicing events affect the reading frames and give rise to the new putative ORFs. Most of the new ORFs have the same start codon as the full length ORF of LDH-C make it likely that at least some of these putative ORFs are used for translation leading to the generation of the corresponding polypeptides. However, when the putative polypeptides encoded by human and rat splicing variants were compared with the corresponding full length LDH-C protein, the results showed that these putative polypeptides were truncated LDH-C proteins or truncated LDH-C protein with a few amino acid residues at N-terminal or C-terminal different from LDH-C (Fig. 2). The results suggest that the variants are possibly not used for translation but probably targets of NMD (Lejeune and Maguat, 2005). Western blot were performed to analyze the putative polypeptides, all the putative polypeptides encoded by the variants were below 34 kDa and however the western blotting didn't detect any bands below 34 kDa. The reasons may be that the sensitivity of western blotting is not enough to detect these putative polypeptides or the variants can not be translated into proteins. These findings also suggest the possibility that RNA alternative splicing might involve in regulation of LDH-C expression in testes development.

From the RT-PCR results of rat testis tissues, we found that the mRNA level of the splicing variants were significant during the development of testes. This may indicate that the transcription repression of LDH-C was loosening in testes. Previous reports showed that LDH-C was silenced in non-testes tissues, however we did cloned one splicing variants in heart, muscle and liver of rat, so it is possible that one or several copies of LDH-C pre-mRNA may escape from transcription repression in non-testis tissues. Koslowski et al. (2002) reported that multiple splicing variants of LDH-C were expressed in significant levels in a broad spectrum of human tumors but not in normal testicular tissue. Surprisingly, our experiments showed that the alternative splicing variants of LDH-C also exist in normal human and rat testes tissues and non-testes tissues (even though their expression level is very low). We did not detect any variants with full length ORF (999 bp) in normal rat non-testes tissues, but Koslowski and his colleagues did detect in human cancers. The expression levels of splicing variants were significant in rat testes. It is interesting that the expression level of splicing variants in cancers were also significant. This may suggest that the transcription repression of LDH-C was loosen in cancers (like in rat testes). One hypothese for ectopic expression of testis-specific genes in cancer cells (CTAs, cancer/testis-associated genes) is the induction or activation of a gametogenic program in cancer (Old, 2001). Since alternative splicing play an important role in gene regulation, we suggest that focus on RNA splicing of CTAs may provide insight into tumor development.

### ACKNOWLEDGMENT

This study was supported by scientific research fund of Sichuan Provinicial Education Department (08ZA096, 12ZB022), scientific research fund of Chengdu Medical College (CYZ09-016) and China Natural Science Foundation (31071700).

#### REFERENCES

- Coonrod, S., A. Vitale, C. Duan, S. Bristol-Gould, J. Herr and E. Goldberg, 2006. Testis-specific lactate dehydrogenase (LDH-C4; Ldh3) in murine oocytes and preimplantation embryos. J. Androl., 27: 502-509.
- Everse, J. and N.O. Kaplan, 1973. Lactate dehydrogenases: Structure and function. Adv. Enzymol. Relat. Areas. Mol. Biol., 37: 61-133.
- Goldberg, E., 1985. Reproductive implications of LDH-C4 and other testis-specific isozymes. Exp. Clin. Immunogenet., 2:120-124.
- He, Q., J. Hong, Y. Zheng and S. Jin, 2008. Cloning and sequence analysis of multiple splice variants of lactate dehydrogenase C in yak testes. J. Reprod. Dev., 54: 229-232.
- Huang, L., Y.Q. Lin, S.Y. Jin, W. Liu, Y.O. Xu and Y.C. Zheng, 2012. Alternative splicing of testisspecific lactate dehydrogenase C gene in mammals and pigeon. Anim. Biotechnol., 23: 114-123.
- Koslowski, M., O. Türeci, C. Bell, P. Krause, H.A. Lehr, J. Brunner, G. Seitz, F.O. Nestle, C. Huber and U. Sahin, 2002. Multiple splice variants of lactate dehydrogenase C selectively expressed in human cancer. Cancer Res., 62: 6750-6755.
- Kroft, T.L., S. Li, L. Doglio and E. Goldberg, 2003. A transgenic analysis of mouse lactate dehydrogenase C promoter activity in the testis. J. Androl., 24: 843-852.
- Lejeune, F. and L.E. Maquat, 2005. Mechanistic links between nonsense-mediated mRNA decay and premRNA splicing in mammalian cells. Curr. Opin. Cell Biol., 17: 309-315.
- Lewis, B.P., R.E. Green and S.E. Brenner, 2003. Evidence for the widespread couplingof alternative splicing and nonsense-mediated mRNA decay in humans. Proc. Natl. Acad. Sci., 100: 189-192.
- Li, S., W. Zhou, L. Doglio and E. Goldberg, 1998. Transgenic mice demonstrate a testis-specific promoter for lactate dehydrogenase, LDHC. J. Biol. Chem., 273: 31191-31194.
- Markert, C.L., T.M. Amet and E. Goldberg, 1998. Human testis-specific lactate dehydrogenase-C promoter drives over expression of mouse lactate dehydrogenase-1 cDNA in testes of transgenic mice. J. Exp. Zool., 282: 171-178.
- Old, L.J., 2001. Cancer/testis (CT) antigens-a new link between gametogenesis and cancer. Cancer Immun., 1: 1.
- Tang, H., A. Kung and E. Goldberg, 2008. Regulation of murine lactate dehydrogenase C (Ldhc) gene expression. Biol. Reprod., 78: 455-461.
- Tang, H. and E. Goldberg, 2009. Homo sapiens lactate dehydrogenase c (Ldhc) gene expression in cancer cells is regulated by transcription factor Sp1, CREB and CpG island methylation. J. Androl., 30: 157-167.

- Thomas, K., D.J. Mazo, P. Eversole, A. Bellvé, Y. Hiraoka, S.S. Li and M. Simon, 1990. Developmental regulation of expression of the lactate dehydrogenase (LDH) multigene family during mouse spermatogenesis. Development, 109(2): 483-493.
- WHO (World Health Organization), 1999. WHO Laboratory Manual for the Examination of Human Semen and Sperm-Cervical Mucus Interactions. 4th Edn., Cambridge University Press, Cambridge, pp: 138.